Partnering to Pioneer Multimodal Spatial Diagnostics
Nucleai and leading research institutions are uniting multimodal AI technology and spatial biology to identify predictive biomarkers and translate discoveries into real-world diagnostic solutions.
At Nucleai, we believe the future of precision medicine lies in multimodal spatial collaboration – connecting clinical expertise, spatial biology, and AI to transform biomarker discovery into deployable diagnostics.
Our partnerships with leading academic and translational research institutions, including the University of Glasgow, are pioneering new approaches to disease prediction, risk stratification, and prevention. These partnerships combine clinical and pathology expertise of academic partners with Nucleai’s scalable multimodal spatial pipeline, the most advanced in the world for spatial proteomics and tissue-level AI analysis. Nucleai’s approach uniquely integrates high dimensionality multimodal data for biomarker discovery, and applies complexity reduction techniques to translate those discoveries into scalable diagnostic tests. Unlike approaches based solely on low-complexity or H&E data, Nucleai’s platform captures a more full biological context of disease, yielding more predictive and clinically actionable tests.
The Global Precision Medicine Network
Through our Precision Medicine Partnerships initiative, Nucleai is building a global network of academic and clinical institutions and life science tools providers to advance multimodal spatial biology and enable accessible, actionable diagnostics across oncology and immune-mediated diseases. Together, we’re defining how spatial data and AI can bring precision medicine into everyday care.
Fill out the form below to learn more about our partnership program.